Ответ критикам "точности"
Автор: Каратеев А.Е.
Журнал: Научно-практическая ревматология @journal-rsp
Рубрика: Дискуссия
Статья в выпуске: 5 т.55, 2017 года.
Бесплатный доступ
Короткий адрес: https://sciup.org/14945865
IDR: 14945865 | DOI: 10.14412/1995-4484-2017-576-579
Список литературы Ответ критикам "точности"
- FitzGerald GA. Imprecision: Limitations to interpretation of a large randomized clinical trial. Circulation. 2017; 135(2): 113-5 DOI: 10.1161/CIRCULATIONAHA.116.026324
- Patrono C, Baigent C. Coxibs, traditional NSAIDs, and cardiovascular safety Post-PRECISION: What we thought we knew then and what we think we know now. Clin Pharmacol Ther. 2017; 102(2): 238-45 DOI: 10.1002/cpt.696
- Муравьев ЮВ. Почему исследование комплексной безопасности целекоксиба при артритах, названное PRECISION, является последним по счету, а не по значимости? Научно-практическая ревматология. 2017; 55(3): 324-6
- Nissen S, Yeomans N, Solomon D, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016 Nov 13 DOI: 10.1056/NEJMoa1611593
- Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr; 2(4): 310-21. Epub 2009 Mar 31 DOI: 10.1158/1940-6207.CAPR-08-0206
- Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006 Aug 31; 355(9): 885-95 DOI: 10.1056/NEJMoa061652
- Fabule J, Adebajo A. Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs. Ther Adv Musculoskelet Dis. 2014 Aug; 6(4): 111-30 DOI: 10.1177/1759720X14541668
- Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13; 284(10): 1247-55 DOI: 10.1001/jama.284.10.1247
- Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006 Mar; 119(3): 255-66 DOI: 10.1016/j.amjmed.2005.09.054
- Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010 Jul 17; 376(9736): 173-9 DOI: 10.1016/S0140-6736(10)60673-3
- Dahlberg LE, Holme I, Hoye K, Ringertz B. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand J Rheumatol. 2009 Mar-Apr; 38(2): 133-43 DOI: 10.1080/03009740802419065
- Varas-Lorenzo С, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013; 22: 559-70. Pub. online 25 April 2013 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.3437
- Xu C, Gu K, Yasen Y, Hou Y. Efficacy and safety of celecoxib therapy in osteoarthritis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016 May; 95(20): e3585 DOI: 10.1097/MD.0000000000003585
- Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004 Aug; 63(8): 931-9 DOI: 10.1136/ard.2003.020313
- Strand V, Simon LS, Dougados M, et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol. 2011 Dec; 38(12): 2625-34 DOI: 10.3899/jrheum.110636
- Wanders A, van der Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005 Jun; 52(6): 1756-65 DOI: 10.1002/art.21054
- Laine L, Kivitz A, Belo A, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol. 2012; 107: 379-86 DOI: 10.1038/ajg.2011.443
- Goldstein J, Hochberg M, Fort J, et al. Clinical trial: the incidence of NSAID-associated en-doscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole mag-nesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010; 32(3): 401-13 DOI: 10.1111/j.1365-2036.2010.04378.x
- Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342: 7086 DOI: 10.1136/bmj.c7086
- McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011 Sep; 8(9): e1001098. Epub 2011 Sep 27 DOI: 10.1371/journal.pmed.1001098
- Gunter BR, Butler KA, Wallace RL, et al. Non-steroidal antiinflammatory drug-induced cardiovascular adverse events: a metaanalysis. J Clin Pharm Ther. 2017 Feb; 42(1): 27-38 DOI: 10.1111/jcpt.12484
Статья
